Clinical trials show that repeated administrations of anti–PD-1 or anti–PD-L1 antibodies produce durable responses in a subset of cancer patients by releasing the effector functions of naturally occurring antitumor cytotoxic T lymphocytes (CTLs) [21,22,29,30,31,32]. This evidence concerns the gene CD274 and cancer.